title: Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment.
abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive disease of unknown cause that conveys a dismal prognosis. In the United States there are currently no licensed therapies for treatment of IPF. The development of effective IPF clinical trials networks across the United States and Europe, however, has led to key developments in the treatment of IPF. Advances in understanding of the pathogenetic processes involved in the development of pulmonary fibrosis have led to novel therapeutic targets. These developments offer hope that there may, in the near future, be therapeutic options available for treatment of this devastating disease.
authors.affiliation: Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK. t.maher@rbht.nhs.uk
authors.forename: Toby M
authors.initials: TM
authors.lastname: Maher
mesh_terms: D000208:Acute Disease; D002986:Clinical Trials as Topic; D055513:Connective Tissue Growth Factor / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000187:drug effects / Q000378:metabolism; D015777:Eicosanoids / Q000494:pharmacology; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy* / Q000378:metabolism* / Q000503:physiopathology; D018793:Interleukin-13 / Q000378:metabolism; D019255:NADPH Oxidases / Q000187:drug effects / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D018418:Th2 Cells / Q000187:drug effects / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000187:drug effects / Q000378:metabolism; D017211:Treatment Failure
chemical_list: C526317:CCN2 protein, human; D016207:Cytokines; D015777:Eicosanoids; D018793:Interleukin-13; D016212:Transforming Growth Factor beta; D055513:Connective Tissue Growth Factor; D019255:NADPH Oxidases; D011494:Protein Kinases